Background This phase II, open-label study evaluated the efficacy and safety of erlotinib as
second-line therapy in non-small-cell lung cancer (NSCLC) patients with brain metastases …

Median survival of patients with brain metastases from nonsmall cell lung cancer (NSCLC) is
poor and more effective treatments are urgently needed. We have evaluated the efficacy of …

Purpose Brain metastasis (BM) is a leading cause of death from non–small-cell lung cancer
(NSCLC). Reasoning that activation of the epidermal growth factor receptor (EGFR) …

Introduction The efficacy of high-dose (1250 mg/d) gefitinib for the treatment of
leptomeningeal metastasis in a patient with lung cancer harboring a mutation in the …

Non-small cell lung cancer (NSCLC) harboring an activating epidermal growth factor
receptor (EGFR) mutation shows good and rapid response to EGFR tyrosine kinase …

Background Median survival of non-small cell lung cancer (NSCLC) patients with brain
metastases is poor. We examined concurrent erlotinib and whole brain radiotherapy (WBRT) …

Importance Use of tyrosine kinase inhibitors (TKIs) is the standard therapy for epidermal
growth factor receptor (EGFR)–mutated non–small cell lung cancer (NSCLC) with brain …

Brain metastases are a common occurrence in non–small-cell lung cancer (NSCLC). The
standard treatment is radiation therapy with or without resection, but chemotherapy is only …

It has been demonstrated that erlotinib is effective in treating patients with brain metastasis
from non‑small‑cell lung cancer. However, the number of studies determining the erlotinib …

Purpose Recent reports indicate that refractory central nervous system (CNS) metastases of
non-small cell lung cancer (NSCLC) are improved by high-dose gefitinib or erlotinib …